Hepatitis C infection associated with renal disease and chronic renal failure

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 2, 2004, Pages 69-77

  Poordad, Fred F ^a   Fabrizi, Fabrizio ^b,c   Martin, Paul ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Chronic renal failure; HCV; Interferon; Renal disease; Renal transplantation

Indexed keywords

ALPHA INTERFERON; AMANTADINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

CHILL; CHRONIC KIDNEY FAILURE; CRYOGLOBULINEMIA; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; ERADICATION THERAPY; FEVER; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HEMODIALYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; INFECTION CONTROL; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER DISEASE; LONG TERM CARE; MONOTHERAPY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; VIRUS TITRATION; VIRUS TRANSMISSION;

GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 4444232172     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832931     Document Type: Review

References (93)

1. Fabrizi F, Martin P, Lunghi G, Ponticelli C. Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: clinical perspectives. Int J Artif Organs 2000;23: 805-816
2. Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis 1998;31: 647-654
3. Lombardi M, Cerrai T, Geatti S, et al. Results of a national epidemiological investigation on HCV infection among dialysis patients. J Nephrol 1999;12:322-327
4. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease. An international collaborative study. Lancet 1999;354:93-99
5. Espinosa M, Martin-Malo A, Alvarez de Lara M, Alijama P. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16:1669-1674
6. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896-1902
7. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001;38:919-934
8. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. The Universitaries Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998;53:1022-1025
9. Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infection among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000;182:1291-1299
10. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000;61:44-51
11. Qian KP, Natov SN, Pereira BJ, Lau JY. Hepatitis C virus mixed genotype infection in patients on haemodialysis. J Viral Hepat 2000;7:153-160
12. Todorov V, Boneva R, Ilieva P, et al. High prevalence of hepatitis C virus infection in one dialysis center in Bulgaria. Nephron 1998;79:222-223
13. Djordjevic V, Stojanovic K, Stojanovic M, Stefanovic V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study. Int J Artif Organs 2000;23:181-188
14. Covic A, Iancu L, Apetrei C, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14:40-45
15. Valtuille R, Moretto H, Lef L, et al. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow up. Clin Nephrol 2002;57: 371-375
16. Marcelli D, Stanhard D, Conte F, et al. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50:1013-1018
17. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998;32:629-634
18. Fabrizi F, Lunghi G, Guarnori I, et al. Virological characteristics of hepatitis C virus infection in chronic hemodialysis patients: a cross-sectional survey. Clin Nephrol 1995;44:49-55
19. Picciotto A, Varagona G, Gurreri G, et al. Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in hemodialysis patients. Nephrol Dial Transplant 1993;8:1115-1117
20. Pol S, Romeo R, Zins B, et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int 1993;44:1097-1100
21. Chan TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 1993;17:5-8
22. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number with HCV infection. J Infect Dis 1993;168:1343-1348
23. Fabrizi F, Martin P, Dixit V, et al. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron 1998;80:428-433
24. Martin P, Carter D, Fabrizi F, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000;69:1479-1484
25. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999;94:3576-3582
26. Saab S, Martin P, Brezina M, et al. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis 2001;37:308-315
27. Saab S, Brezina M, Gitnick G, et al. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 2001;38: 91-97
28. Fabrizi F, Martin P, Dixit V, et al. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis 2000;35:122-129
29. Fabrizi F, Martin P, Dixit V, et al. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am J Nephrol 1999;19:383-388
30. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994;45:1507-1509
31. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995;47:1412-1418
32. Raptopoulou-Gigi M, Spaia S, Garifallos A, et al. Interferon-alpha2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995;10:1834-1837
33. Fernandez JL, Rendo P, Del Pino N, Nephrologists' group for the study of HCV infection, Viola L. A double-blind controlled trial of recombinant interferon-alpha2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hep 1997;4:113-119
34. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-therapy. J Infect Dis 1997;176:1614-1617
35. Chan TM, Wu PC, Lau JYN, Lok ASF, Lai CL, Cheng KP. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997;12:1414-1419
36. Uchihara M, Izumi N, Sakai Y, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998;80:51-56
37. Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti PB. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin 1998;14:141-144
38. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant Interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001;21:435-440
39. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-a2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999;14:2704-2709
40. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001;55:220-226
41. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of Interferon for chronic hepatitis C virus-related hepatitis in kidneys transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001;96:1170-1177
42. Hanrotel C, Toupance O, Lavaud S, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001;88:120-126
43. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001;16:1017-1023
44. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metaanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071-1081
45. Russo MW, Goldsweig CD, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610-1615
46. Izzedine H, Lebon P, Launay-Vacher V, et al. Tolerance and pharmacokinetics of high doses of interpheron-alpha-2a in a hemodialysis patient. Nephron 2001;87:91-92
47. Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J Infect Dis 1983;148:335
48. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alfa IFN-2b in chronic hepatitis C virus undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998;9:2344-2348
49. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2001;16:1729
50. Bruchfeld A, Stahle L, Andersson J, Schvarcx R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001;8:287-292
51. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001;16:193-195
52. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000;34:915-923
53. Martin P, Mitra S, Farrington K, et al. Pegylated (40KDA) interferon alfa-2a (Pegasys) is unaffected by renal impairment. Hepatology 2000;32:370A
54. Lamb MW, Marks IM, Wynohradnyk L, et al. 40 kDa peginterferon alfa-2a (Pegasys) can be administered safely in patients with end-stage renal disease. Hepatology 2001;34:326A
55. Bunnapradist S, Fabrizi F, Vierling J, et al. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs 2002;25:1189-1193
56. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-999
57. Zucker K, Cirocco R, Roth D, et al. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 1994;57:832-840
58. Roth D, Fernandez JA, Babishkin S, et al. Transmission of hepatitis C virus solid organ transplantation: incidence and clinical significance. Transplant Proc 1993;25:1476-1477
59. Tesi RJ, Waller K, Morgan ML, Ferguson RM. Transmission of hepatitis C by kidney transplantation-the risks. Transplantation 1994;57:826-831
60. Vincenti F, Lake J, Wright T, et al. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients. Transplantation 1993;55:674-675
61. Fabrizi F, Marai P, Raffaele L, et al. Hepatitis C virus infection in kidney graft recipients: a study with second-generation assays. Nephrol Dial Transplant 1992;7:1164-1165
62. Rostaing L, Izopet J, Cisterne JM, et al. Prevalence of antibodies to hepatitis C virus and correlation with liver disease in renal transplant patients. Am J Nephrol 1997;17:46-52
63. Lau JYN, Davis GL, Brunson ME, et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993;18: 1027-1031
64. Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45:238-244
65. Chan TM, Lok ASF, Chang IKP. Hepatitis C in renal transplant recipients. Transplantation 1991;52:810-813
66. Mahmoud I, Sobh MA, Am GM, et al. Prospective study of hepatitis C viremia in renal allograft recipients. Am J Nephrol 1999;19:576-585
67. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998;53:1374-1381
68. Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997;29:608-614
69. Kliem V, van den Hoff U, Brunkhorst R, et al. The long-term course of hepatitis C after kidney transplantation. Transplantation 1996;62:1417-1421
70. Gentil MA, Rocha JL, Rodriguez-Algarra G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999;14:2455-2460
71. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257-263
72. Batty DS, Swanson SJ, Kirk AD, et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001;1:179-184
73. Rostaing L, Izopet J, Baron E, et al. Treatment of chronic hepatitis C with recombinant Interferon alpha in kidney transplant recipients. Transplantation 1995;59:1426-1431
74. Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995;10:2104-2106
75. Thervet E, Pol S, Legendre C, et al. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994;58:625-628
76. Garnier JL, Chevallier P, Dubernard JM, et al. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997;29:783
77. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000;15:74-76
78. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-756
79. Ferri C, Marzo E, Longombardo G. Interpheron alpha in mixed cryoglobulinemia patients: a randomized, cross-over controlled trial. Blood 1993;81:1132-1136
80. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type-II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-3343
81. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994;46:1700-1704
82. Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 1999;14:1558-1560
83. Qyigg RJ, Brathwaite M, Gardner DF, et al. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis 1995;25:798-800
84. Gilli P, Stabellini N, Storari A, et al. Effect of human leukocyte alpha interferon on cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplant 1996;11:526-538
85. Sarac E, Bastacky S, Johnson JP. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997;30:113-115
86. Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995;25:67-69
87. Morosetti M, Sciarra G, Meloni C, et al. Membranoproliferative glomerulonephritis and hepatitis C: Effects of interferon-alpha therapy on clinical outcome and histologic pattern. Nephrol Dial Transplant 1996;11:532-534
88. Garini G, Allegri L, Carnevali L, et al. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C-virus associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001;38:E35
89. D'Amico G. Nephrology forum: Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998;54:650-671
90. Baid S, Cosimi AB, Tolkoff-Rubin N, et al. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000;70:255-261
91. Davis CL, Gretch DR, Perkins JD, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transpl Surg 1995;3:166-175
92. Kendrick EA, McVicar JP, Kowdley KV, et al. Renal disease in hepatitis C-positive liver transplant recipients. Transplantation 1997;63:1287-1293
93. Pham HP, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998;54:1311-1319